Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
319.43
-0.99 (-0.31%)
At close: Jul 7, 2026, 4:00 PM EDT
319.43
0.00 (0.00%)
After-hours: Jul 7, 2026, 4:27 PM EDT
Ligand Pharmaceuticals Revenue
Ligand Pharmaceuticals had revenue of $51.72M in the quarter ending March 31, 2026, with 14.09% growth. This brings the company's revenue in the last twelve months to $274.48M, up 51.24% year-over-year. In the year 2025, Ligand Pharmaceuticals had annual revenue of $268.09M with 60.40% growth.
Revenue (ttm)
$274.48M
Revenue Growth
+51.24%
P/S Ratio
22.81
Revenue / Employee
$5,839,915
Employees
47
Market Cap
6.33B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 268.09M | 100.95M | 60.40% |
| Dec 31, 2024 | 167.13M | 35.82M | 27.28% |
| Dec 31, 2023 | 131.31M | -64.93M | -33.09% |
| Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
| Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
| Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
| Dec 31, 2019 | 120.28M | -131.17M | -52.17% |
| Dec 31, 2018 | 251.45M | 110.35M | 78.21% |
| Dec 31, 2017 | 141.10M | 32.13M | 29.48% |
| Dec 31, 2016 | 108.97M | 37.06M | 51.53% |
| Dec 31, 2015 | 71.91M | 7.38M | 11.43% |
| Dec 31, 2014 | 64.54M | 15.57M | 31.78% |
| Dec 31, 2013 | 48.97M | 17.59M | 56.02% |
| Dec 31, 2012 | 31.39M | 1.35M | 4.50% |
| Dec 31, 2011 | 30.04M | 6.50M | 27.61% |
| Dec 31, 2010 | 23.54M | -15.40M | -39.55% |
| Dec 31, 2009 | 38.94M | 11.63M | 42.56% |
| Dec 31, 2008 | 27.32M | 14.42M | 111.84% |
| Dec 31, 2007 | 12.89M | 8.92M | 224.21% |
| Dec 31, 2006 | 3.98M | -6.24M | -61.07% |
| Dec 31, 2005 | 10.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.14B |
| PTC Therapeutics | 827.11M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 5.07M |
| CRISPR Therapeutics AG | 4.10M |
LGND News
- 12 days ago - Ligand Announces Closing of Convertible Senior Notes Offering - GlobeNewsWire
- 14 days ago - Ligand prices upsized $625M convertible senior note offering - TheFly
- 14 days ago - Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering - GlobeNewsWire
- 15 days ago - Ligand files to sell $550M of convertible senior notes due 2031 - TheFly
- 15 days ago - Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 - GlobeNewsWire
- 27 days ago - Ligand Announces 2026 Investor Day in New York City - GlobeNewsWire
- 5 weeks ago - Ligand price target raised to $266 from $263 at BofA - TheFly
- 5 weeks ago - Ligand to Participate in June Investor Conferences - GlobeNewsWire